News on Compulsory Licensing in Malaysia:

April 4, 2013- The Malaysian Insider: Dr M, Malay chamber want Najib to reject free trade deal with Washington (links to

October 22, 2012-The Star (Malaysia): Measure to make drugs affordable (links to

May 18, 2012 - Pharmalot: Malaysians Seek License for Abbott AIDS Drug (links to Pharmalot) 

March 14, 2012-Update from Malaysia: Personal Statement on Abbott Laboratories' Kaletra

Actions in Malaysia


 "The Malaysian AIDS Council (MAC) is throwing its support on the Global Action on Kaletra, a coalition of non-government organisations (NGOs) across the developing world that work together as a single voice in urging Abbott Laboratories to free up patent restrictions on the components of HIV medicine commercially known as Kaletra (Lopinavir/ritonavir).

'We stand in solidarity with the Global Action on Kaletra. We are delighted that a concerted global respond towards this pressing is currently underway. We believe commitment by pharmaceutical corporations on fair trade practice is a critical step to achieve the goal of universal access for HIV treatment by 2015,' remarked Tan Sri Mohammad Zaman Khan, President of the Malaysian AIDS Council.

Through the availability of affordable generic drugs, the Government of Malaysia has been able to provide select anti-retroviral (ARV) medication for free since 2005. However, due to patent restrictions, newer generation of ARVs such as Kaletra have become so excessively expensive that they limit our Government's ability to provide greater access to medication for people living with HIV."

                                    --Malaysian AIDS Council World AIDS Day Statement on Kaletra


In Malaysia, Kaletra costs 11,400 MYR (~$3,585) per person per year (ppy), while 2010 per capita GDP was $8,373.

The Malaysian AIDS Council sent a letter to Abbott requesting an open license, which would enable Malaysia to import (or produce) affordable generic lopinavir+ritonavir in exchange for reasonable royalty payments to Abbott.

See the Malaysian AIDS Council's letter to Abbott Laboratories here.

NEW! On May 3, 2012, the Malaysian AIDS Council sent a letter to the Ministry of Health requesting a government use license for the patents that are necessary to use lopinavir/ritonavir and ritonavir. Read it here (links to

To help educate people about what it's like for people living with HIV in Malaysia who depend on Kaletra to survive, Nazarius Celsus Dorus of Malaysia's PT Foundation has shared a statement about his personal experiences:

 "I have had to tighten my belt because Kaletra is so expensive for me. I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need"

Read Nazarius' full statement here

Return to the Kaletra Campaign Homepage

Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.